BR112016024457A2 - anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo - Google Patents
anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpoInfo
- Publication number
- BR112016024457A2 BR112016024457A2 BR112016024457A BR112016024457A BR112016024457A2 BR 112016024457 A2 BR112016024457 A2 BR 112016024457A2 BR 112016024457 A BR112016024457 A BR 112016024457A BR 112016024457 A BR112016024457 A BR 112016024457A BR 112016024457 A2 BR112016024457 A2 BR 112016024457A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- isolated
- immunoconjugate
- producing
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
a invenção diz respeito aos anticorpos anti-her3 que se ligam ao grampo beta (beta-hairpin) de her3, à preparação destes anticorpos e ao uso destes como medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14168335 | 2014-05-14 | ||
PCT/EP2015/060492 WO2015173250A1 (en) | 2014-05-14 | 2015-05-12 | Anti-her3 antibodies binding to the beta-hairpin of her3 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016024457A2 true BR112016024457A2 (pt) | 2018-01-23 |
Family
ID=50729374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016024457A BR112016024457A2 (pt) | 2014-05-14 | 2015-05-12 | anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo |
Country Status (12)
Country | Link |
---|---|
US (1) | US9783611B2 (pt) |
EP (1) | EP3143048B1 (pt) |
JP (1) | JP6433511B2 (pt) |
KR (1) | KR20160144465A (pt) |
CN (1) | CN106459207B (pt) |
AR (1) | AR100426A1 (pt) |
BR (1) | BR112016024457A2 (pt) |
CA (1) | CA2944895A1 (pt) |
MX (1) | MX2016014416A (pt) |
RU (1) | RU2016148682A (pt) |
TW (1) | TW201605902A (pt) |
WO (1) | WO2015173250A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150955A1 (es) | 2012-11-08 | 2015-06-20 | Hoffmann La Roche | Proteinas ligantes de antigeno anti-her3/her4 de union a la horquilla beta de her3 y a la horquilla beta de her4 |
CA2884431A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
BR112016025056A2 (pt) | 2014-05-14 | 2018-02-20 | F. Hoffmann-La Roche Ag | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica |
EP3143048B1 (en) | 2014-05-14 | 2019-08-28 | F. Hoffmann-La Roche AG | Anti-her3 antibodies binding to the beta-hairpin of her3 |
US20220072144A1 (en) * | 2018-09-20 | 2022-03-10 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
JP4262594B2 (ja) | 2001-06-22 | 2009-05-13 | エフ.ホフマン−ラ ロシュ アーゲー | レトロウイルス表面糖タンパク質を含む可溶性複合体 |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
JP2009532393A (ja) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ErbB受容体由来ペプチド断片 |
NZ574093A (en) | 2006-06-12 | 2011-03-31 | Symphogen As | Pan-cell surface receptor- specific therapeutics |
PL2716301T3 (pl) * | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
CA2759792A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
RU2012149227A (ru) | 2010-05-20 | 2014-06-27 | Аблинкс Нв | Биологические материалы, относящиеся к her3 |
CU24094B1 (es) | 2010-08-20 | 2015-04-29 | Novartis Ag | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2788382A2 (en) * | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
CN104159924B (zh) | 2011-12-05 | 2018-03-16 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
PE20150955A1 (es) * | 2012-11-08 | 2015-06-20 | Hoffmann La Roche | Proteinas ligantes de antigeno anti-her3/her4 de union a la horquilla beta de her3 y a la horquilla beta de her4 |
CA2884431A1 (en) * | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
EP3143048B1 (en) | 2014-05-14 | 2019-08-28 | F. Hoffmann-La Roche AG | Anti-her3 antibodies binding to the beta-hairpin of her3 |
-
2015
- 2015-05-12 EP EP15721719.1A patent/EP3143048B1/en active Active
- 2015-05-12 CN CN201580022781.7A patent/CN106459207B/zh not_active Expired - Fee Related
- 2015-05-12 CA CA2944895A patent/CA2944895A1/en not_active Abandoned
- 2015-05-12 RU RU2016148682A patent/RU2016148682A/ru not_active Application Discontinuation
- 2015-05-12 MX MX2016014416A patent/MX2016014416A/es unknown
- 2015-05-12 BR BR112016024457A patent/BR112016024457A2/pt not_active Application Discontinuation
- 2015-05-12 US US14/710,194 patent/US9783611B2/en active Active
- 2015-05-12 KR KR1020167031609A patent/KR20160144465A/ko not_active Application Discontinuation
- 2015-05-12 JP JP2016567203A patent/JP6433511B2/ja not_active Expired - Fee Related
- 2015-05-12 WO PCT/EP2015/060492 patent/WO2015173250A1/en active Application Filing
- 2015-05-13 TW TW104115311A patent/TW201605902A/zh unknown
- 2015-05-13 AR ARP150101480A patent/AR100426A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN106459207B (zh) | 2020-07-10 |
JP6433511B2 (ja) | 2018-12-05 |
CA2944895A1 (en) | 2015-11-19 |
EP3143048B1 (en) | 2019-08-28 |
CN106459207A (zh) | 2017-02-22 |
JP2017521050A (ja) | 2017-08-03 |
US20160002338A1 (en) | 2016-01-07 |
EP3143048A1 (en) | 2017-03-22 |
MX2016014416A (es) | 2017-02-23 |
RU2016148682A (ru) | 2018-06-19 |
AR100426A1 (es) | 2016-10-05 |
WO2015173250A1 (en) | 2015-11-19 |
KR20160144465A (ko) | 2016-12-16 |
TW201605902A (zh) | 2016-02-16 |
US9783611B2 (en) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016025056A2 (pt) | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica | |
EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
BR112019004998A2 (pt) | anticorpos anti-pd-1(cd279) | |
BR112016020112A2 (pt) | anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CL2016001723A1 (es) | Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos. | |
BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
AR099465A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
BR112017001579A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112016010706A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo | |
BR112018006350A2 (pt) | anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo | |
BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
CL2014003140A1 (es) | Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso. | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
UY36889A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
UA117364C2 (uk) | Похідні аматоксину | |
BR112015024553A2 (pt) | anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio | |
BR112017009813A2 (pt) | conjugados de anticorpo fármaco |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |